Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-07-24Clinical Trial Update: A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients [Phase 1, Phase 2]
A Phase 1/2 trial evaluating the combination of obinutuzumab (GDC-0199) and ibrutinib in relapsed/refractory mantle cell lymphoma has comple…
-
CLINICAL_TRIALS trial_result · 2025-07-23Clinical Trial Update: Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma [Phase 2]
This Phase 2 trial assessed rituximab in combination with chemotherapy for patients with previously untreated mantle cell lymphoma. Results …
-
CLINICAL_TRIALS trial_result · 2025-07-22Clinical Trial Update: Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) [Phase 3]
Phase 3 trial assessing ibrutinib in combination with venetoclax for mantle cell lymphoma has completed, and its results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-07-16Clinical Trial Update: Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma
A completed follow-up study evaluating a CD19 CAR-T cell therapy engineered to express IL7 and CCL19 for relapsed or refractory B-cell lymph…
-
CLINICAL_TRIALS trial_result · 2025-07-10Clinical Trial Update: Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. [Phase 3]
A phase 3 trial comparing lenalidomide plus rituximab followed by lenalidomide versus rituximab maintenance in relapsed/refractory follicula…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-07-04Clinical Trial Update: UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep [Phase 2]
Phase 2 clinical trial evaluating non-myeloablative preparative regimens followed by umbilical cord blood transplantation for various hemato…
-
CLINICAL_TRIALS research · 2025-06-24Clinical Trial Update: Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders [Phase 2]
Phase 2 clinical trial evaluating myeloablative allogeneic hematopoietic stem cell transplantation from related or unrelated donors for a br…
-
CLINICAL_TRIALS trial_result · 2025-06-18Clinical Trial Update: A Phase 1 Study of ADI-001 in B Cell Malignancies [Phase 1]
The Phase 1 study of ADI-001 in B cell malignancies has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-06-17Clinical Trial Update: JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 study of JWCAR239 for B-cell non-Hodgkin lymphoma is not yet recruiting, with indications including diffuse large B-cell lymphoma, f…
-
CLINICAL_TRIALS trial_result · 2025-06-13Clinical Trial Update: Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma [Phase 2]
Phase II trial of venetoclax plus rituximab as initial therapy for older patients with mantle cell lymphoma has been terminated.
-
FDA approval · 2025-06-10FDA Approved: BRUKINSA — Original Application (BeOne Medicines USA, Inc.)
The FDA approved the original application for Brukinsa (zanubrutinib) from BeOne Medicines USA, Inc., marking the U.S. approval of this BTK …
-
CLINICAL_TRIALS trial_result · 2025-06-10Clinical Trial Update: Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial of selinexor in combination with ibrutinib for relapsed or refractory chronic lymphocytic leukemia and aggressive non-Hodgkin …
-
CLINICAL_TRIALS trial_result · 2025-06-06Clinical Trial Update: Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL [Phase 2]
This trial update reports Phase 2 results for a triple regimen of acalabrutinib, lenalidomide, and rituximab in patients with untreated Mant…
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation [Phase 2]
Phase 2 trial comparing three GVHD prophylaxis regimens in nonmyeloablative or reduced-intensity conditioning unrelated donor transplantatio…
-
CLINICAL_TRIALS research · 2025-06-03Clinical Trial Update: Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination of acalabrutinib and rituximab in elderly or low- to intermediate-risk younger patien…
-
CLINICAL_TRIALS research · 2025-05-28Clinical Trial Update: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) [Phase 3]
Phase 3 study comparing LOXO-305 (pirtobrutinib) with approved BTK inhibitors in mantle cell lymphoma; the trial is currently active but not…
-
FDA approval · 2025-05-22FDA Approved: LENALIDOMIDE — Original Application (Devatis Inc.)
FDA approved a generic lenalidomide under the original application from Devatis Inc., enabling market access for this established cancer the…
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating dendritic cell therapy with cryosurgery and pembrolizumab in various Non-Hodgkin lymphoma subtypes, w…
-
CLINICAL_TRIALS trial_result · 2025-05-13Clinical Trial Update: Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma [Phase 2]
Phase 2 trial results evaluating acalabrutinib after blood or marrow transplantation in mantle cell lymphoma; results posted in May 2025.
-
CLINICAL_TRIALS trial_result · 2025-05-13Clinical Trial Update: The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma [EARLY_Phase 1]
Early-phase phase 1 study evaluating the combination of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed/refractory mantle cel…
-
CLINICAL_TRIALS research · 2025-05-11Clinical Trial Update: Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients [Phase 2]
A Phase 2 trial evaluating the combination of Sonrotoclax, Zanubrutinib, and a CD20 monoclonal antibody in untreated mantle cell lymphoma is…
-
CLINICAL_TRIALS trial_result · 2025-04-27Clinical Trial Update: RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 study evaluating everolimus (RAD001) in relapsed or refractory hematologic malignancies, including leukemia, mantle ce…
-
CLINICAL_TRIALS trial_result · 2025-04-25Clinical Trial Update: Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma [Phase 1]
A Phase 1 trial evaluating the combination of Abexinostat and Ibrutinib in diffuse large B-cell lymphoma and mantle cell lymphoma has comple…
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma [Phase 1]
Phase 1 results from a three-drug combination (CC-486/azacitidine, lenalidomide, and obinutuzumab) in patients with recurrent or refractory …
-
CLINICAL_TRIALS other · 2025-04-24Clinical Trial Update: DALY II USA/ MB-CART2019.1 for DLBCL [Phase 2]
Miltenyi Biomedicine's MB-CART2019.1 (DALY II) is in Phase 2 for refractory/relapsed B-cell lymphomas, including Diffuse Large B-Cell Lympho…